TCTR20211022002招募中3 期
Efficacy and safety of an Andrographis capsule compared with standard therapy for the treatment of asymptomatic or mild COVID-19 without pneumonia : A double-blinded randomized-control trial
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 736
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 60 Years（—）
- 性别
- All
入选标准
- •1. Age 18-60 years old
- •2. Have been diagnosed as a new case by RT-PCR within 72 hours
- •3. Have no symptoms or mild symptoms which do not need medication such as low grade fever (body temperature less than 38 degree celcius) cough, runny nose, sore throat, body aches, headache, loss of taste, loss of smell
- •4. Have resting oxygen Saturation not less than 96% and SpO2 changes after performing exercise-induced desaturation less than 3%
- •5. Have respiratory rate not over 20 breaths per minute
- •6. Have normal chest x-ray
- •7. Have no underlying diseases or under control for more than 6 months
- •8. Willing to participate in the study
排除标准
- •1. Have history of AP allergy
- •2. Receive antiviral, antibiotic, chloroquine, hydroxychloroquine, ivermectin, interferon within 7 days prior to admission
- •3. Receive AP or other herbal medicines for COVID-19 treatment within 7 days prior to admission
- •4. Receive immunosuppressant agents within 6 months prior to admission
- •5. Receive anticoagulant agents, statins, amlodipine, clozapine, phenytoin
- •6. Are pregnant or lactating women
- •7. Have risk factors for COVID-19 progression such as Chronic Obstructive Pulmonary Disease, Chronic Kidney Disease, Cardiovascular Diseases, congenital heart diseases, cerebrovascular disease, uncontrolled diabetes, obesity (BMI greater than 30kg/m2), liver cirrhosis, weakened immune system, cancer and lymphocyte less than 1,000 cells/ mm3
- •8. Have WHO clinical progression scale greater than 3
- •9. AST or ALT levels greater than 3 times the upper reference limit
- •10. GFR lower than 30 mL/min/1.73 m2
研究者
相似试验
已完成
1 期
Safety and pharmacokinetic studies of Andrographis paniculata extracts in Thai healthy volunteersHealthy volunteers with normal physical examination and vital signsScreening visit laboratory of the blood test are within the normal range.Healthy volunteersSafetyPharmacokineticsTCTR20210201005Thailand Science Research and Innovation (TSRI)48
已完成
3 期
The efficacy and safety of Andrographis paniculata extract for the treatment of acute nonspecific upper respiratory tract infections: a randomized double-blind placebo controlled trialAcute nonspecific upper respiratory tract infections with one or more symptoms such as fever,sore throat,nasal congestion,dry infrequent cough and had modified Centor Score of 2 or less.Andrographis paniculataandrographolideacute nonspecific upper respiratory tract infectionspharyngitiscommon coldTCTR20170329002Department of Thai Traditional and Alternative Medicine829
已完成
2 期
Comparison efficacy and safety of Andrographis paniculata extract capsules and placebo in COVID-19 patients: Double blind randomized control trialCOVID-19 patient with asymptomatic and mild symptomatic. Progression score between 0-3. (Green color)COVID-19AndrographolideTCTR20210809004Thammasat university186
已完成
1 期
Efficacy and safety of Andrographis paniculata extract in patients with mild COVID-19: A randomized controlled trialTCTR20210708001Thai Traditional Medicine Knowlegde funding63
招募中
3 期
Efficacy and safety of Andrographis paniculata extract for the treatment of asymptomatic or mild-symptoms COVID-19 patients: A double-blinded, randomized-control trialCOVID-19 patienrs, RT-PCR confirmedCovid-19 treatmentAndrographidis paniculatae extractPneumoniaTCTR20211224002Health System Research Institute736